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The distinction between tubular carcinomas (TC) and
invasive well-differentiated (grade 1) ductal carcinoma
(IDC) is important given treatment and prognostic differ-
ences. Studies have described a strong association
between flat epithelial atypia (FEA) and TC. The incidence
of FEA associated with grade 1 IDC is not well established.
The aim of the present study was to assess morphology and
intra-epithelial lesions between 14 TC and 18 grade 1 IDC
matched for size. Of 14 TC, eight (57%) had associated FEA,
seven (50%) had micropapillary atypical ductal hyperplasia
(ADH), three (21%) had low nuclear grade ductal carcinoma
in situ (DCIS), and four (29%) had lobular neoplasia. Notably,
only two of 18 (11%) grade 1 IDC had associated FEA. Three
of 18 (16%) grade 1 IDC had ADH, two (11%) had lobular
neoplasia, and seven (39%) had DCIS. All tubular carcino-
mas were estrogen receptor (ER) positive and negative for
Her-2/neu overexpression. All grade 1 IDC were ER positive
but 5% also overexpressed Her-2/neu. Axillary lymph node
metastasis was present in 11% of grade 1 IDC and absent in
TC. A strong association was found between TC, FEA, and
micropapillary ADH, which may reflect a biological progres-
sion. Despite matching for tumor size, grade 1 IDC have a
higher incidence of lymph node metastasis and may have
Her-2-neu overexpression compared to TC.
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Tubular carcinomas (TC) of the breast are uncommon
tumors, accounting for <2% of all invasive breast carcinomas.
They are low-grade carcinomas characterized by prominent
glandular differentiation with fewer reported genetic alter-
ations (recurrent loss of 16q, gain of 1 q) compared to inva-
sive ductal carcinoma.1,2 The differences between TC and
well-differentiated grade 1 invasive ductal carcinomas (grade
1 IDC) warrant further study.
The importance of differentiating TC from IDC is under-
scored by data showing that TC have a lower incidence of
axillary lymph node metastasis and fewer recurrences.3–6
Recent studies have documented an association between
TC and micropapillary and cribriform ductal carcinoma in situ
(DCIS) as well as flat epithelial atypia (FEA).7,8 FEA is a
descriptive term for an intraductal alteration characterized by
replacement of native epithelial cells by a single or 3–5 layers
of monotonous atypical cuboidal to columnar cells with apical
snouts, and is distinguished from columnar cell change and
columnar cell hyperplasia by the presence of mild cytological
atypia, and from atypical ductal hyperplasia (ADH) and DCIS
by the absence of architectural atypia.
The incidence of intraductal proliferations occurring in
association with grade 1 IDC is not well-established. We
systematically assessed the pathological features and con-
comitant intra-epithelial lesions associated with TC and
grade 1 IDC matched for size to better understand the his-
topathology of these lesions and identify features that may
help in the differential diagnosis.
MATERIALS AND METHODS
Study population
We identified all TC diagnosed at University of Michigan
School of Medicine between January 1998 and August
2006 following excision biopsy. Grade 1 IDC diagnosed on
excisions and matched for size, were also retrieved from
the surgical Pathology files. All cases were retrospectively
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evaluated by the authors (LPK and CGK). We applied strict
criteria for the diagnosis of TC i.e. the tubular component
accounted for at least 90% of tumor as recommended by
the World Health Organization (WHO) Working Group on the
Pathology and Genetics of Tumors of the Breast.9 The grade
1 IDC selected for study were well-differentiated, with low-
grade nuclei, no prominent specialized pattern, and failed to
exhibit characteristics diagnostic of a specific histological
type. Importantly, the grade 1 IDC included in the present
study were matched for size with TC (median size 0.8 cm and
0.9 cm for TC and grade 1 IDC, respectively) in order to avoid
the bias of disparity in carcinoma dimension between the two
groups.
Morphological review
Morphological parameters evaluated in the present study
included (i) presence of angulated glands with open lumina,
apical snouts, nuclear grade, and stromal cellularity; (ii) pres-
ence of associated intra-epithelial lesions including FEA,
atypical lobular hyperplasia (ALH), lobular carcinoma in situ
(LCIS), ADH and DCIS. Although at present there is no
unequivocal agreement on whether quantitative criteria
should be applied to separate ADH from low-grade DCIS, in
the present study ADH was diagnosed following the criteria
established by WHO.9 Thus, ADH was diagnosed when there
was a proliferation of evenly distributed monomorphic cells
growing in different patterns (micropapillary, cribriform) but
that coexisted with usual ductal hyperplasia, and/or there
was partial involvement of duct.
All the available slides of excision biopsies were reviewed
by two study authors (LPK and CGK). The slides per case
ranged from six to 13 slides. Statistical analyses were per-
formed by the biostatistician in our group (YD) using Pear-
son’s c2 test. P < 0.05 was considered statistically significant.
Clinical information
Clinical information including hormone receptors (estrogen
receptor, ER; progesterone receptor, PR) and Her-2/neu
status as well as axillary lymph node involvement were
reviewed for all cases when available.
Immunohistochemistry (ER, PR and Her-2/neu)
Hormone receptors (ER and PR) as well as Her-2/neu were
assessed on immunohistochemistry using a refined labeled
streptavidin–biotin technique (LSAB+ Kit, HRP; Dako Cyto-
mation, Carpinteria, CA, USA) for ER and PR. Following
paraffin removal and hydration, slides were treated with Tris
(0.25 mol/L)-EDTA (0.1 mmol/L) buffer, pH 9.0 in a micro-
wave pressure cooker for 15 min for optimal antigen retrieval
before immunostaining. Cases were stained with monoclonal
antibodies against ER (clone 6F11, 1:100 dilution; Ventana
Medical Systems, Tucson, AZ, USA), PR (clone 636, 1:400
dilution; Dako Cytomation) and Her-2/neu ( (clone CB11;
Ventana Medical Systems) for 32 min at 42°C on 4 mm-thick
sections obtained from formalin-fixed paraffin-embedded
blocks. A Ventana Basic DAB Detection Kit was used accord-
ing to manufacturer’s specifications for Her-2/neu. Staining
was performed on the Ventana BenchMark XT platform
(Ventana Medical Systems).
Only nuclear staining for ER and PR was evaluated quan-
titatively (>5% tumor cells staining was considered positive).
Her-2/neu immunoreactivity was semiquantified according to
the following established grading scheme: negative or 0, no
or any detectable membrane staining in <10% of tumor cells;
1+, weak, incomplete membrane staining in >10% of tumor
cells; 2+, moderate staining (proportion and intensity of stain-
ing between 1+ and 3+ scores) i.e. weak to moderate com-
plete staining in >10% of tumor cells; and 3+, strong,
complete membrane staining in >30% of the tumor cells.
Cytoplasmic staining was not included in the grading
scheme. On immunohistochemistry a score of 2+ or 3+ was
considered Her-2-neu overexpression.
Fluorescence in situ hybridization (Her-2/neu)
Fluorescence in situ hybridization (FISH) for confirmation of
Her-2/neu overexpression was performed on all cases with
2+ immunohistochemistry score at the Mayo Clinic, Roches-
ter, MN, USA according to previously described established
procedure. Briefly, FISH was performed using PathVysion
DNA Probe Kit (Vysis, Downers Grove, IL, USA). Unstained
4 mm slides were deparaffinized, dehydrated and air-dried.
Following an average of 60 min of protease digestion and
denaturation, tissue sections were hybridized for 16 h at
37°C with prewarmed probes for the Her-2 gene and
chromosome 17 centromere (Her-2/neu/CEP 17, Abbott
Molecular/Vysis, Des Plaines, IL, USA). After hybridization
the slides were washed, counterstain was applied and slides
were coverslipped and sealed. Her-2 signals were quantified
in the area of invasive tumor and at least 30 non-overlapping
interphase cell nuclei were evaluated. In each nucleus the
number of Her-2 and chromosome 17 centromere signals
were counted and the Her-2 : CEP 17 ratio was calculated. A
ratio >2.2 was considered a positive result (amplification of
Her-2/neu by FISH).
RESULTS
Fourteen TC and 18 grade 1 IDC matched for size were
retrieved for analysis. Table 1 summarizes the patient char-
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acteristics and morphological features. The median age of
the patients was 56.7 years (range, 36–81 years) for
TC and 60 years (range, 39–94 years) for grade 1 IDC.
The median tumor size was 0.8 cm (range, 0.2–1.50
and 0.9 (range, 0.4–1.3 cm) for TC and grade 1 IDC,
respectively.
All TC had >90% angulated glands with open lumina
(Fig. 1a). Of the 18 grade 1 IDC, 17% (n = 3) had prominent
tubular architecture, with angulated glands accounting for
50–75% of the tumor, and was regarded as ‘mixed type
carcinoma’ as per the WHO classification of breast tumors.
The remaining 83% of grade 1 IDC (15/18) had <50% angu-
lated glands. Fused glands and/or cords of tumor cells were
seen in 72% of IDC (13/18; Fig. 1d) and were absent in all
TC. Prominent apical snouts (involving >50% of tumor cells)
were present in the vast majority of TC (93%, 13/14) while
they were rare in grade 1 IDC (11%, 2/18). Furthermore, the
stroma was myxoid and/or fibroblastic in both TC and grade
1 IDC. Presence of angulated glands, fused glands/cords
and apical snouts was significantly more common in TC
when compared to grade 1 IDC (P < 0.0001). No significant
differences were found in the stromal characteristics of the
tumors.
Table 2 lists the frequency of FEA and other intra-epithelial
lesions in TC and grade 1 IDC. FEA was almost an exclusive
feature of TC. In the TC group FEA was present in 57% of
TC (8/14) while it was seen in 11% of grade 1 IDC (2/18;
P = 0.005). The most common morphological pattern of FEA
(7/8) was that of a lobular well-circumscribed configuration
of variably distended terminal ducts (blunt duct adenosis
pattern on low power (10¥); Fig. 1c) whereas the large
cystically dilated ducts with flocculent secretions in lumen
was uncommon (1/8). In all cases, regardless of the low-
power appearance, the cells lining the acini and ducts had
low-grade atypia characterized by epithelial cells with round
to ovoid nuclei, slightly increased nuclear–cytoplasm ratio,
and loss of polarity with disorganization of nuclei relative to
the basement membrane. The ADH and DCIS lesions asso-
ciated with TC had a cribriform and/or micropapillary growth
pattern in all cases (Fig. 1b). TC was associated with FEA
and micropapillary ADH in 50% (7/14), of which cribriform
low-grade DCIS was also present in 21% (3/14).
FEA was rare in grade 1 IDC, being present in 11% (2/18).
Interestingly, the two grade 1 IDC tumors with associated
FEA had tubular features but did not meet the criteria for pure
TC, because the tubular differentiation was <90% of tumor.
The reminder of the grade 1 IDC (16/18) did not contain FEA.
Ten of 18 grade 1 IDC tumors (55%) had ADH and DCIS, with
most having cribriform architecture (8/10; Fig. 1e,f). A solid
pattern of growth was less common (2/10). Micropapillary
ADH or DCIS was focally present in one of three grade 1 IDC
with tubular features.
Lobular intra-epithelial lesions, ALH and/or LCIS, were
observed in 29% of TC (4/14)and were less frequently asso-
ciated with grade 1 IDC (11%, 2/18 cases), but this was not
statistically significant (P = 0.21). TC was associated with
FEA and ALH/LCIS in 15% (2/14).
As shown in Table 3, although lymph node metastasis
developed in 11% of patients with grade 1 IDC (2/18), they
were absent in all patients with TC. All TC were positive for






Median age (range) (years) 56.7 (36–81) 60 (39–94)
Median size (range) (cm) 0.8 (0.2–1.5) 0.9 (0.4–1.3)
Angulated glands with open lumina
>90% 14 (100) 0
50–90% 0 3 (17)
<50% 0 15 (83)
<0.0001
Fused glands and/or cords 0 13 (72)
<0.0001
Apical snouts
>50% 14 (100) 2 (11)
25–49% 0 3 (17)
5–24% 0 8 (44)
<5% 0 5 (28)
<0.0001
Stromal characteristics
Myxoid 7 (50) 6 (33)
Fibrotic 7 (50) 12 (67)
NS
IDC, invasive ductal carcinoma; TC, tubular carcinoma; NS, not significant.
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ER, and 64% (9/14) were positive for PR. All grade 1 IDC
were positive for ER and 83% (15/18) were also positive for
PR. Of note, Her-2/neu overexpression was detected on
immunohistochemistry in 7% of TC (1/14) and in 17% of
grade 1 IDC (3/18). FISH confirmed the amplification of Her-
2/neu in 5% of grade 1 IDC (1/3) while the TC, as well as two
grade 1 IDC with Her-2/neu overexpression on immunohis-
tochemistry, were negative on FISH.
a b c
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Figure 1 Intra-epithelial lesions including flat epithelial atypia (FEA) in tubular carcinoma (TC) and grade 1 invasive ductal carcinoma (IDC).
(a) TC composed of haphazardly arranged round and angulated glands with open lumens and apical snouts surrounded by fibroblastic stroma
(HE). (b) Micropapillary atypical ductal hyperplasia (ADH; arrow) with adjacent TC (arrowheads; HE). (c) FEA with blunt adenosis pattern
(arrow) characterized by flat growth pattern (no complex architecture, unlike ADH) and cytological atypia similar to low nuclear grade ductal
carcinoma in situ (DCIS). The cells of FEA lack polarity with respect to basement membrane and have round to ovoid nuclei with occasional
nucleoli. Note adjacent TC. (d) Well-differentiated (grade 1 IDC) composed of predominantly fused glands as well as cords of cells with few
single glands in a myxoid stroma (HE). (e) Cribriform ADH in a single duct characterized by cribriform proliferation of relatively monomorphic
cells with occasional overlapping of cells (note that cells are not as uniform as they would be in low-nuclear grade DCIS) with adjacent grade
1 IDC (HE). (f) Cribriform low-nuclear grade DCIS with grade 1 IDC characterized by uniform cells with round nuclei and sharp punched out
lumina (HE).








Flat epithelial atypia 8 (57) 2 (11) (P = 0.005)
Lobular neoplasia (ALH/LCIS) 4 (29) 2 (11) (NS)
Atypical ductal hyperplasia 7 (50) 3 (16) (P = 0.04)
Ductal carcinoma in situ 3 (21) 7 (39) (NS)
ALH, atypical lobular hyperplasia; IDC, invasive ductal carcinoma; LCIS, lobular carcinoma in situ; NS, not significant.
















TC (n = 14) 14 (100) 9 (64) 1 (7) 0 0
Grade 1 IDC (n = 18) 18 (100) 15 (83) 3 (17) 1 (5) 2 (11) (NS)
ER, estrogen receptor; FISH, fluorescence in situ hybridization; IHC, immunohistochemistry; NS, not statistically significant; PR, progesterone
receptor; TC, tubular carcinoma
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DISCUSSION
In the present study we analyzed morphological character-
istics, precursor intra-epithelial lesions, hormone receptor,
Her-2/neu overexpression and lymph node status of TC in
comparison with size-matched grade 1 IDC tumors, with the
aim of identifying pathological characteristics that could be
applied to daily surgical pathology practice.
TC has an excellent prognosis, with the survival of patients
with tubular carcinoma being similar to that of the general
population.10 Furthermore, because of the rare incidence of
metastasis, adjuvant systemic therapy has been recom-
mended for large tumors, usually >3 cm, and adjuvant radia-
tion therapy following breast conservation therapy is not
recommended by some groups.10,11 Therefore, it is imperative
that a definitive diagnosis of TC is made following strict
histological criteria. Furthermore, defining the intraductal
putative precursor lesions associated with TC that may help
in the differential diagnosis with grade 1 IDC would be helpful
in daily pathology practice.
Historically, there has been a lack of consensus among
pathologists concerning the proportion of tubular structures
required to establish the diagnosis of TC. Although it is inher-
ently assumed that all TC have a prominent tubular configu-
ration, several early studies did not have specific cut-offs,
while other authors have used percentages of tubular struc-
tures ranging from 70% to 100%.8,12–14 Thus, although there
is a body of literature on the features of TC, it is difficult to
compare results among these studies given the different
definitions used. Recently, the WHO Working Group on the
Pathology and Genetics of Tumors of the Breast made the
recommendation that 90% of tubules are needed to establish
the diagnosis of TC.9 This definition was used in the present
study. Once the definition is applied, TC are usually small; the
median size of TC in the present series was 0.8 cm with the
majority (10/14) being <1 cm. We noted that even matching
the tumors for size, TC had less lymph node metastasis than
grade 1 IDC. Not surprisingly, we found that TC do not
overexpress Her-2/neu, in contrast with a very small group of
grade 1 IDC.
Goldstein and O’Malley reported that ‘cancerization of
small ectatic ducts by DCIS cells with apocrine snouts’, a
term that now is designated as FEA, is associated with TC in
43.7% of cases.15 Recent studies, as well as the present
series (57% of TC associated with FEA, P = 0.005), have
confirmed the strong association between FEA and TC,
which may reflect a biological progression.7,8 The present
findings are in agreement with those of Fernandez-Aguilar
et al. and Goldstein and O’Malley (47.8% and 43.7%, respec-
tively),8,15 in that we found that FEA is significantly associated
with TC.
To the best of our knowledge only two studies have
attempted to compare precursor lesions between TC and
grade 1 IDC.7,15 Both studies are in agreement with the
present findings that FEA is more commonly associated with
TC than with grade 1 IDC. In the present study we noted FEA
in two grade 1 IDC that had tubular features (50–75% of
tubules) but which did not meet the criteria for TC.
We found that the majority of DCIS lesions in both TC and
grade 1 IDC are of low nuclear grade, supporting the fact that
a good correlation exists between the histological grade of
DCIS and the grade of the associated invasive carcinoma.8,16
Interestingly,ADH and DCIS lesions arising in association with
TC commonly show micropapillary and/or cribriform architec-
ture, while a solid growth pattern of DCIS is uncommon in the
setting of TC.7,15,17 We noted that the triad of TC, FEA, and
micropapillary ADH/DCIS is present in 50% of TC, and postu-
late that there may be a biological progression. We also found
an association between TC and ALH, LCIS, and FEA.
In summary, the present data validate the fact that TC is a
distinct tumor entity that has lower incidence of axillary lymph
node metastasis and no Her-2/neu overexpression when
compared to size-matched grade 1 IDC. Although in isolation,
morphological features including the presence of angulated
glands and/or apical snouts are not helpful morphological
features in distinguishing TC from grade 1 IDC, the combi-
nation of these features in the absence of fused glands
and/or cords is a strong diagnostic tool for TC. FEA is
strongly associated with TC and with the tubular component
of mixed tumors. The strong association between TC, micro-
papillary ADH and FEA found in the present study under-
score the investigation of these lesions in the pathobiology
of TC.
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